NCT02760758View on ClinicalTrials.gov

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

April 30, 2017

Conditions
Hepatitis C
Interventions
DRUG

CDI-31244

NNI

DRUG

Placebo

no active ingredients

Trial Locations (1)

Unknown

Algorithme, Montreal

Sponsors
All Listed Sponsors
lead

Cocrystal Pharma, Inc.

INDUSTRY